Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

Beneficial preventive and therapeutic effects of halofuginone in liver cirrhosis

Nov. 16, 1999

DAPD and L-FMAU compared for in vitro anti-HBV activity using wild-type and resistant strains

Nov. 16, 1999

Safety and preliminary efficacy of HBV/MF59 vaccine: data presented at AASLD

Nov. 16, 1999

Beta-L-FD4C compared to lamivudine in woodchuck model of chronic HBV infection

Nov. 16, 1999

FR-167653 examined in rat model of hepatic ischemia/reperfusion injury

Nov. 15, 1999

rhIL-10 reduces liver injury, normalizes serum ALT in HCV patients failing interferon

Nov. 15, 1999

CDP-571 is effective in Crohn's disease: phase IIb study results announced

Nov. 15, 1999

AASLD presentations support feasibility of ribozyme therapy in HCV

Nov. 12, 1999

Phase II data support further study of VX-497 for hepatitis C

Nov. 12, 1999

Preliminary phase II results promising for Maxamine in HCV

Nov. 11, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...